In the buzzing world of IPOs, Anthem Biosciences Ltd has made quite a splash. With its IPO receiving an astronomical subscription rate of 63.86 times, all eyes are now locked on the next big reveal—the allotment status. If you’ve invested in this biotech heavyweight’s offering, you’re probably refreshing your screen in anticipation.
But don’t worry—we’ve got your back. In this blog, we’ll walk you through every essential detail about the IPO, its subscription frenzy, how to check your allotment status using PAN, and even dive into the grey market premium (GMP). Let’s decode this step-by-step.
Overview of Anthem Biosciences IPO
What is Anthem Biosciences?m
For those unfamiliar, Anthem Biosciences Ltd is a leading contract research and manufacturing organization (CRMO) based in India. The company specializes in providing comprehensive R&D and manufacturing services in the pharmaceutical, biotechnology, and life sciences industries. From drug discovery to custom synthesis, Anthem has carved a reputation for delivering high-quality, scalable solutions to global clients.
This IPO marks a major milestone in their corporate journey, aimed at expanding their facilities, investing in new technologies, and furthering R&D capabilities. And with the biotech sector seeing immense growth post-COVID, the timing couldn’t be more strategic.
Highlights of the IPO Launch
The IPO officially opened on July 14, 2025, and closed on July 16, 2025. The price band was set between Rs 540 and Rs 570 per share, making it appealing for both institutional and retail investors. With a face value of Rs 10 per equity share, the company aimed to raise significant capital to boost their infrastructure and product development.
The mainboard IPO also appointed KFin Technologies Ltd as its official registrar, ensuring a smooth process for applications and allotments.
Subscription Details: Record-Breaking Demand
Day-by-Day Bidding Breakdown
It’s no exaggeration to say the Anthem Biosciences IPO was a hit. From the moment the window opened, investors rushed in, pushing subscription numbers to unprecedented levels. Here’s a breakdown of how the bidding fared:
-
Day 1 (July 14): A slow but steady start with heavy interest from qualified institutional buyers (QIBs).
-
Day 2 (July 15): Retail investors and high-net-worth individuals (HNIs) began piling in, raising the bid volume significantly.
-
Day 3 (July 16): The final day saw an explosive surge in bids across all categories, leading to an oversubscription of 63.86 times.
Key Statistics from the Bidding
According to NSE data, the IPO saw bids for a whopping 2,81,44,34,740 shares, while only 4,40,70,682 shares were on offer. That’s an eye-watering level of demand! Here’s a snapshot:
-
QIBs: Oversubscribed massively, indicating strong institutional faith.
-
HNIs: Participated enthusiastically due to promising GMP and growth prospects.
-
Retail Investors: Despite limited quota, they jumped in, showing belief in the company’s vision.
This intense subscription gives a strong signal that the IPO has been priced attractively and holds solid long-term potential.
IPO Allotment Status: What You Need to Know
Finalization Date and Timeline
Now comes the moment of truth—the IPO allotment status. As per the official schedule, the basis of allotment is expected to be finalized today, July 17, 2025. This process determines how many shares have been allotted to each investor based on subscription levels and demand.
Once finalized, registrars will begin notifying investors via SMS or email, depending on your registered contact details. If you’re lucky, your Demat account could see a neat bundle of Anthem shares in the next few days.
Expected Listing Date on Stock Exchanges
According to the IPO prospectus, Anthem Biosciences is slated to be listed on the BSE and NSE on July 21, 2025. That’s just around the corner! Investors who are allotted shares can expect them to be credited to their Demat accounts shortly before this date, possibly by July 20.
Until then, it’s best to keep checking your status using your PAN or application number, as explained in the next section.
Step-by-Step Guide to Check IPO Allotment Status
How to Check Anthem Biosciences IPO Status on BSE
Want to check your status via BSE? It’s pretty simple. Just follow these steps:
-
Go to the BSE IPO allotment status page: bseindia.com/investors/appli_check.aspx
-
Select ‘Equity’ under the issue type.
-
Choose ‘Anthem Biosciences IPO’ from the drop-down list.
-
Enter your PAN or application number correctly.
-
Click on ‘Submit’ to view your status.
If you’ve been allotted shares, the message will confirm it. Otherwise, it’ll say “No Records Found” — meaning you didn’t get the allocation this time.
How to Check IPO Status via KFin Technologies
Alternatively, you can also check through KFin Technologies, the registrar to the issue:
-
Visit the official link: https://ris.kfintech.com/ipostatus/
-
Select ‘Anthem Biosciences IPO’ from the drop-down menu.
-
Enter your PAN, Application Number, or DP/Client ID.
-
Click on ‘Search’ to know your status.
If successful, you’ll see the number of shares allotted. If not, better luck next time!
Grey Market Premium (GMP) Update
What the GMP Tells US
As of today, the grey market premium (GMP) for Anthem Biosciences is Rs 148. This means the shares are trading unofficially at Rs 718 in the grey market, well above the upper price band of Rs 570. That’s a solid indicator of strong investor interest and confidence in the stock’s listing performance.
Grey market trading gives us a sneak peek into how the stock might perform on listing day. While not always accurate, it’s often used by seasoned investors to gauge sentiment and expected listing gains.
Market Sentiment and Future Expectations
The high GMP, along with overwhelming subscription numbers, paints a bullish picture for the Anthem Biosciences IPO. Analysts predict a listing pop, possibly in the range of 20% to 30%, depending on broader market conditions.
If the market remains steady, Anthem could very well become the next biotech star on the bourses. Long-term investors may want to hold on, given the company’s strong fundamentals and R&D-driven model.
And also read our latest blog : GPAT 2025: Today’s Result, Final Answer Key, Cutoff Dates & Counselling Guide
